• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

COVID-19 Convalescent Plasma Improves Outcomes for Cancer Patients

January 10, 2023

Standard COVID-19 therapies and vaccines have limited effectiveness in patients with impaired humoral immune responses, and these patients have a high risk of severe COVID-19.  High titer COVID-19 convalescent plasma (CCP) used early in the disease has been shown to reduce the risk of hospitalization among immunocompetent outpatients. A new randomized clinical trial from Germany supports CCP use in patients with cancer.  From September 2020 to January 2022, 134 high risk patients with PCR-confirmed SARS-CoV-2 infections (mean age=69 years, 32.1% female, 11.2% fully vaccinated) were randomized to receive either standard care (n=66) or standard care in addition to two units of ABO-compatible, high titer CCP (titers >1:80) (n=68) on the day of randomization (average of 7 days after symptom onset).  Four high-risk groups were evaluated:  1) cancer (n=56, hematologic and solid); 2) immunosuppression (n=16); 3) lymphopenia/elevated D-dimers (n=36); 4) age>75 years (n=26).  Although no differences in outcomes were seen when all the risk-groups were combined, patients with cancer who received CCP improved more quickly (HR=2.50; P=0.003) and had increased survival compared to the control arm (HR=0.28; P=0.42).  Unlike monoclonal antibodies and vaccines, convalescent plasma, has the potential to evolve in real-time with the virus and may be an important component of treating patients with cancer and COVID-19.

Reference:

Denkinger, C.M., Janssen, M., Schäkel, U. et al. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nat Cancer (2022).

Filed Under

  • Coagulation & Plasma Transfusion
  • News

Recommended

  • NIH Urges Randomized Controlled Trials for COVID-19 Convalescent Plasma

  • Liberal versus Restrictive Transfusion Thresholds for Patients with Subarachnoid Hemorrhage

  • Platelet Rich Plasma Injections Are Not Beneficial for Acute Hamstring Injuries

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Array-based, comprehensive genotyping for erythroid, platelet, neutrophil and leukocyte antigens

  • Acute Normovolemic Hemodilution Does Not Reduce RBC Transfusions

  • Blood Donation Teams—a Novel Strategy to Support Novice Donors

  • Plasma Exchange to Reduce Biological Age

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley